Olson Scott
Known title: SVP & Pres, Rhythm ManagementCIK: 0001816850
Associated companies
Transaction History
| BSX | ▼ Sell | Open Market | 700 | $31K | 4/1/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 766 | $34K | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,426 | $0 | 2/28/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,090 | $0 | 2/21/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 606 | $26K | 2/21/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,037 | $0 | 2/18/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 510 | $22K | 2/18/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,416 | $0 | 2/17/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 713 | $31K | 2/17/2022 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,292 | $0 | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 707 | $31K | 2/15/2022 | View on chart |
| BSX | ▼ Sell | Open Market | 700 | $30K | 1/3/2022 | View on chart |
| BSX | ▼ Sell | Open Market | 700 | $30K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.